Bicara Therapeutics Inc. BCAX
Set alert
9.13 USD -0.60 -6.17%
At close · Oct 30
8.98 -0.15 -1.65%
After hours · Oct 30, 7:42 PM ET
8.36 Day range 9.38
9.13 52-week range 30.40
- YTD
- -45.75%
- 1 year
- -44.53%
- Open
- 9.38
- Prev close
- 9.73
- Mkt cap
- 604.16M
- Vol
- 4.20M
- Avg vol
- 1.03M
- EPS
- -3.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.36
- High
- 9.38
- Forward P/E
- -4.96
- Beta
- -0.69
- Short ratio
- 16.85
- Inst. own
- 102.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 20.82
- 200-d avg
- 21.33
- 1y target
- 35.67
MAX chart
Events in this range
- Aug 12, 2025Earnings: -0.5; estimate -0.54; surprise 7.41%
- Nov 10, 2025Earnings: -0.67; estimate -0.55; surprise -21.82%
- Mar 26, 2026Earnings: -0.68; estimate -0.72; surprise 5.56%
- May 11, 2026Earnings: -0.93; estimate -0.64; surprise -45.31%
- Aug 11, 2026Earnings: -0.82; estimate -0.81978; surprise -0.03%
- Aug 12, 2026Rating: Mizuho · Neutral → Neutral
- Aug 12, 2026Rating: Morgan Stanley · Overweight → Overweight
- Aug 12, 2026Rating: Wedbush · Outperform → Outperform
- Aug 12, 2026Rating: Goldman Sachs · Neutral → Neutral
- Aug 19, 2026Rating: BMO Capital · — → Outperform
- Oct 19, 2026Rating: BTIG · Buy → Buy
Signals (38)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 22, 2025 | 10 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
Financial health
Altman Z-Score
6.94 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -6.7×
FY 2022 5y median -18.7× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 2.3×
FY 2022 5y median 2.1× FY 2025
P/FCF -8.6×
FY 2022 5y median -19.4× FY 2025
EV/EBITDA -6.0×
FY 2022 5y median -12.8× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -11.6%
FY 2022 5y median -5.9% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -34.4%
FY 2022 5y median -18.8% FY 2025
ROIC -38.6%
FY 2022 5y median -16.6% FY 2025
ROA -32.0%
FY 2022 5y median -27.1% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -88.9%
FY 2022 FY 2025
EPS (diluted) -101.6%
FY 2022 FY 2025
Free Cash Flow -43.2%
FY 2022 FY 2025
Financial Health
Current Ratio 14.6×
FY 2022 5y median 14.9× FY 2025
Quick Ratio 14.6×
FY 2022 5y median 14.9× FY 2025
Debt / Equity 0.0×
FY 2022 5y median 0.0× FY 2025
Net Debt / EBITDA 0.7×
FY 2022 5y median 2.6× FY 2025
Interest Coverage 0.0×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31